
Business UpdateNov 13, 2026, 08:31 AM
AIM ImmunoTech: Ampligen Pancreatic Cancer Study Nears Data Readout
AI Summary
AIM ImmunoTech Inc. announced progress in its Phase 2 DURIPANC study for Ampligen® in metastatic pancreatic cancer, with dosing complete and primary endpoint analysis set for December 2026. Topline results are expected in Q1 2027, followed by survival data in mid-2027, which will inform pivotal Phase 3 development. The company is also exploring Ampligen's potential synergy with emerging RAS-targeted therapies. Financial results for Q3 2026 showed a cash position of $6.9 million, increased R&D expenses of $846,000, and a net loss of $3.1 million.
Key Highlights
- AIM ImmunoTech Inc. reported Q3 2026 financial results and provided a business update on Ampligen®.
- Dosing completed in Phase 2 DURIPANC study for pancreatic cancer; primary endpoint analysis begins December 2026.
- Topline clinical benefit results from DURIPANC study anticipated in Q1 2027.
- Median overall survival and immune-response data from DURIPANC study expected mid-year 2027.
- Company exploring Ampligen's potential complementary role with emerging RAS-targeted therapies.
- Q3 2026 cash, cash equivalents, and marketable securities totaled approximately $6.9 million.
- Q3 2026 R&D expenses were approximately $846,000, up from $607,000 year-over-year.
- Q3 2026 net loss was approximately $3.1 million, compared to $3.3 million in Q3 2025.
Price Impact
More from AIM